SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AMBA

Ambarella Inc (NASDAQ:AMBA)

US · Delayed Price · Currency is USD
Also listed: 0YU1.LTechnology · Semiconductors
66.82+0.32 (+0.48%)
 
Market cap
$2.95B
Health Score
Analyst consensus
Listed since
Oct 10, 2012
Insider Score
––Not scored
AMBA Insider Score

Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.

AMBA analyst forecast

AMBA analyst consensus

Moderate Buy4 ratings
Buy 2 Hold 2 Sell 0

Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.

AMBA 12-month price target

$70.00+4.8% upsideaverage of 1 firm
$70.00High
$70.00Low

Best analysts covering AMBA

  • Susquehanna50%success rate · 12 calls
  • Rosenblatt35%success rate · 20 calls
  • Needham31%success rate · 16 calls
  • Stifel27%success rate · 15 calls

Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.

AMBA analyst ratings

FirmPrice targetAction
—RosenblattBuy——Reiterated2026-09-16
—Roth CapitalNeutral——Reiterated2026-09-04
—RosenblattBuy——Reiterated2026-09-04
—B of A SecuritiesNeutral——Reiterated2026-09-04
—StifelBuy——Reiterated2026-09-04
Craig-Hallum—$70.00+10.4%—2026-09-04
—RosenblattBuy——Reiterated2026-08-31
—RosenblattBuy——Reiterated2026-05-29
—SusquehannaPositive——Reiterated2026-05-29
—B of A SecuritiesNeutral——Reiterated2026-05-29
—RosenblattBuy——Reiterated2026-05-26
—RosenblattBuy——Reiterated2026-03-23
—NeedhamBuy——Reiterated2025-11-26
—B of A SecuritiesNeutral——Reiterated2025-11-26
—RosenblattBuy——Reiterated2025-11-26
—StifelBuy——Reiterated2025-11-26
—RosenblattBuy——Reiterated2025-11-24
—OppenheimerPerform——Reiterated2025-08-29
—Northland Capital MarketsOutperform——Reiterated2025-08-29
—B of A SecuritiesNeutral——Reiterated2025-08-29
—RosenblattBuy——Reiterated2025-08-29
—StifelBuy——Reiterated2025-08-29
—Morgan StanleyOverweight——Reiterated2025-08-29
—NeedhamBuy——Reiterated2025-08-29
—SusquehannaPositive——Reiterated2025-07-22
—RosenblattBuy——Reiterated2025-05-30
—NeedhamBuy——Reiterated2025-05-30
—Morgan StanleyOverweight——Reiterated2025-05-27
—StifelBuy——Reiterated2025-04-17
—RosenblattBuy——Reiterated2025-02-27
—NeedhamBuy——Reiterated2025-02-27
—StifelBuy——Reiterated2025-02-27
—SusquehannaPositive——Reiterated2025-01-22
—RosenblattBuy——Reiterated2024-12-06
—Morgan StanleyOverweight——Reiterated2024-11-27
—Craig-HallumBuy——Reiterated2024-11-27
—B of A SecuritiesUnderperform——Reiterated2024-11-27
—SusquehannaPositive——Reiterated2024-11-27
—Northland Capital MarketsOutperform——Reiterated2024-11-27
—NeedhamBuy——Reiterated2024-11-27
—StifelBuy——Reiterated2024-11-27
—SusquehannaPositive——Reiterated2024-10-21
—NeedhamBuy——Reiterated2024-08-28
—Craig-HallumBuy——Reiterated2024-08-28
—TD CowenHold——Reiterated2024-08-28
—WestPark CapitalBuy——Reiterated2024-08-28
—Morgan StanleyOverweight——Reiterated2024-08-28
—StifelBuy——Reiterated2024-08-28
—B of A SecuritiesUnderperform——Reiterated2024-08-28
—Roth MKMNeutral——Reiterated2024-08-28
—WestPark CapitalBuy——Reiterated2024-08-26
—RosenblattBuy——Reiterated2024-08-23
—RosenblattBuy——Reiterated2024-06-11
—Wells FargoEqual Weight——Reiterated2024-05-31
—NeedhamBuy——Reiterated2024-05-31
—Morgan StanleyOverweight——Reiterated2024-05-31
—Roth MKMNeutral——Reiterated2024-05-31
—RosenblattBuy——Reiterated2024-05-29
—B of A SecuritiesUnderperform——Reiterated2024-04-16
—NeedhamBuy——Reiterated2024-02-28

AMBA earnings vs. estimates

QuarterEPS est.EPS actualRevenue est.Revenue actual
2026-02-260.100.13$100.2M$100.9M
2026-05-280.100.11$100.1M$100.4M
2026-09-030.170.18$107.8M$108.1M
2026-12-010.320.00$119.5M$0
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.